[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 53, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 57, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 594612, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 339819, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 48, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 365556, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 53, "title": "Chief Corporate & Business Development Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 339300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 63, "title": "Chief Commercial Officer, President of RedHill Biopharma Inc. & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 469802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Senior Business Development & Investor Relations Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Reza  Fathi Ph.D.", "age": 68, "title": "Senior Vice President of Research & Development", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 299291, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Goldberg J.D.", "age": 47, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 338126, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.53, "open": 9.5, "dayLow": 8.7, "dayHigh": 9.6276, "regularMarketPreviousClose": 9.53, "regularMarketOpen": 9.5, "regularMarketDayLow": 8.7, "regularMarketDayHigh": 9.6276, "beta": 3.626, "trailingPE": 0.09020001, "forwardPE": 300.6667, "volume": 114736, "regularMarketVolume": 114736, "averageVolume": 307974, "averageVolume10days": 212405, "averageDailyVolume10Day": 212405, "bid": 8.91, "ask": 9.19, "bidSize": 200, "askSize": 200, "marketCap": 11550471, "fiftyTwoWeekLow": 6.425, "fiftyTwoWeekHigh": 82.0, "priceToSalesTrailing12Months": 1.7688317, "fiftyDayAverage": 9.91335, "twoHundredDayAverage": 16.368477, "currency": "USD", "enterpriseValue": 70981648384, "profitMargins": 3.6624799, "floatShares": 7421347249, "sharesOutstanding": 1280540, "sharesShort": 16697, "sharesShortPriorMonth": 19656, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0005, "heldPercentInstitutions": 0.11533, "shortRatio": 1.46, "shortPercentOfFloat": 0.0005, "bookValue": 2.629, "priceToBook": 3.4309626, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": 23916000, "trailingEps": 100.0, "forwardEps": 0.03, "enterpriseToRevenue": 10870.084, "enterpriseToEbitda": -3204.011, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RDHL", "underlyingSymbol": "RDHL", "shortName": "Redhill Biopharma Ltd.", "longName": "RedHill Biopharma Ltd.", "firstTradeDateEpochUtc": 1357569000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "55b47776-7c51-3ec7-bc27-c300c5d6081d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.02, "targetHighPrice": 19000.0, "targetLowPrice": 19000.0, "targetMeanPrice": 19000.0, "targetMedianPrice": 19000.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 5569000, "totalCashPerShare": 0.001, "ebitda": -22154000, "totalDebt": 1173000, "quickRatio": 0.46, "currentRatio": 0.839, "totalRevenue": 6530000, "debtToEquity": 56.694, "revenuePerShare": 25.2, "returnOnAssets": -0.15713, "freeCashflow": -18231876, "operatingCashflow": -35820000, "revenueGrowth": -0.956, "grossMargins": 0.47029, "operatingMargins": -10.607929, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-26"}]